Sphingolipidomics of A2780 human ovarian carcinoma cells treated with synthetic retinoids
The dihydroceramide, ceramide, sphingomyelin, lactosylceramide, and ganglioside species of A2780 human ovarian carcinoma cells treated with the synthetic retinoids N-(4-hydroxyphenyl)retinamide (fenretinide, 4-HPR) and 4-oxo-N-(4-hydroxyphenyl)retinamide (4-oxo-4-HPR) in culture were characterized b...
Main Authors: | , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2010-07-01
|
Series: | Journal of Lipid Research |
Subjects: | |
Online Access: | http://www.sciencedirect.com/science/article/pii/S0022227520371054 |
id |
doaj-9369513b8fac414aa4643b20545a1d66 |
---|---|
record_format |
Article |
spelling |
doaj-9369513b8fac414aa4643b20545a1d662021-04-28T06:01:54ZengElsevierJournal of Lipid Research0022-22752010-07-0151718321840Sphingolipidomics of A2780 human ovarian carcinoma cells treated with synthetic retinoidsManuela Valsecchi0Massimo Aureli1Laura Mauri2Giuditta Illuzzi3Vanna Chigorno4Alessandro Prinetti5Sandro Sonnino6Department of Medical Chemistry, Biochemistry and Biotechnology, Center of Excellence on Neurodegenerative Diseases, University of Milano, 20090 Segrate, ItalyDepartment of Medical Chemistry, Biochemistry and Biotechnology, Center of Excellence on Neurodegenerative Diseases, University of Milano, 20090 Segrate, ItalyDepartment of Medical Chemistry, Biochemistry and Biotechnology, Center of Excellence on Neurodegenerative Diseases, University of Milano, 20090 Segrate, ItalyDepartment of Medical Chemistry, Biochemistry and Biotechnology, Center of Excellence on Neurodegenerative Diseases, University of Milano, 20090 Segrate, ItalyDepartment of Medical Chemistry, Biochemistry and Biotechnology, Center of Excellence on Neurodegenerative Diseases, University of Milano, 20090 Segrate, ItalyDepartment of Medical Chemistry, Biochemistry and Biotechnology, Center of Excellence on Neurodegenerative Diseases, University of Milano, 20090 Segrate, ItalyTo whom correspondence should be addressed; Department of Medical Chemistry, Biochemistry and Biotechnology, Center of Excellence on Neurodegenerative Diseases, University of Milano, 20090 Segrate, ItalyThe dihydroceramide, ceramide, sphingomyelin, lactosylceramide, and ganglioside species of A2780 human ovarian carcinoma cells treated with the synthetic retinoids N-(4-hydroxyphenyl)retinamide (fenretinide, 4-HPR) and 4-oxo-N-(4-hydroxyphenyl)retinamide (4-oxo-4-HPR) in culture were characterized by ESI-MS. We characterized 32 species of ceramide and dihydroceramide, 15 of sphingomyelin, 12 of lactosylceramide, 9 of ganglioside GM2, and 6 of ganglioside GM3 differing for the long-chain base and fatty acid structures. Our results indicated that treatment with both 4-HPR and 4-oxo-4-HPR led to a marked increase in dihydroceramide species, while only 4-oxo-4-HPR led to a minor increase of ceramide species. Dihydroceramides generated in A2780 cells in response to 4-HPR or 4-oxo-4-HPR differed for their fatty acid content, suggesting that the two drugs differentially affect the early steps of sphingolipid synthesis. Dihydroceramides produced upon treatments with the drugs were further used for the synthesis of complex dihydrosphingolipids, whose levels dramatically increased in drug-treated cells.http://www.sciencedirect.com/science/article/pii/S00222275203710544-HPRfenretinide4-oxo-4-HPR |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Manuela Valsecchi Massimo Aureli Laura Mauri Giuditta Illuzzi Vanna Chigorno Alessandro Prinetti Sandro Sonnino |
spellingShingle |
Manuela Valsecchi Massimo Aureli Laura Mauri Giuditta Illuzzi Vanna Chigorno Alessandro Prinetti Sandro Sonnino Sphingolipidomics of A2780 human ovarian carcinoma cells treated with synthetic retinoids Journal of Lipid Research 4-HPR fenretinide 4-oxo-4-HPR |
author_facet |
Manuela Valsecchi Massimo Aureli Laura Mauri Giuditta Illuzzi Vanna Chigorno Alessandro Prinetti Sandro Sonnino |
author_sort |
Manuela Valsecchi |
title |
Sphingolipidomics of A2780 human ovarian carcinoma cells treated with synthetic retinoids |
title_short |
Sphingolipidomics of A2780 human ovarian carcinoma cells treated with synthetic retinoids |
title_full |
Sphingolipidomics of A2780 human ovarian carcinoma cells treated with synthetic retinoids |
title_fullStr |
Sphingolipidomics of A2780 human ovarian carcinoma cells treated with synthetic retinoids |
title_full_unstemmed |
Sphingolipidomics of A2780 human ovarian carcinoma cells treated with synthetic retinoids |
title_sort |
sphingolipidomics of a2780 human ovarian carcinoma cells treated with synthetic retinoids |
publisher |
Elsevier |
series |
Journal of Lipid Research |
issn |
0022-2275 |
publishDate |
2010-07-01 |
description |
The dihydroceramide, ceramide, sphingomyelin, lactosylceramide, and ganglioside species of A2780 human ovarian carcinoma cells treated with the synthetic retinoids N-(4-hydroxyphenyl)retinamide (fenretinide, 4-HPR) and 4-oxo-N-(4-hydroxyphenyl)retinamide (4-oxo-4-HPR) in culture were characterized by ESI-MS. We characterized 32 species of ceramide and dihydroceramide, 15 of sphingomyelin, 12 of lactosylceramide, 9 of ganglioside GM2, and 6 of ganglioside GM3 differing for the long-chain base and fatty acid structures. Our results indicated that treatment with both 4-HPR and 4-oxo-4-HPR led to a marked increase in dihydroceramide species, while only 4-oxo-4-HPR led to a minor increase of ceramide species. Dihydroceramides generated in A2780 cells in response to 4-HPR or 4-oxo-4-HPR differed for their fatty acid content, suggesting that the two drugs differentially affect the early steps of sphingolipid synthesis. Dihydroceramides produced upon treatments with the drugs were further used for the synthesis of complex dihydrosphingolipids, whose levels dramatically increased in drug-treated cells. |
topic |
4-HPR fenretinide 4-oxo-4-HPR |
url |
http://www.sciencedirect.com/science/article/pii/S0022227520371054 |
work_keys_str_mv |
AT manuelavalsecchi sphingolipidomicsofa2780humanovariancarcinomacellstreatedwithsyntheticretinoids AT massimoaureli sphingolipidomicsofa2780humanovariancarcinomacellstreatedwithsyntheticretinoids AT lauramauri sphingolipidomicsofa2780humanovariancarcinomacellstreatedwithsyntheticretinoids AT giudittailluzzi sphingolipidomicsofa2780humanovariancarcinomacellstreatedwithsyntheticretinoids AT vannachigorno sphingolipidomicsofa2780humanovariancarcinomacellstreatedwithsyntheticretinoids AT alessandroprinetti sphingolipidomicsofa2780humanovariancarcinomacellstreatedwithsyntheticretinoids AT sandrosonnino sphingolipidomicsofa2780humanovariancarcinomacellstreatedwithsyntheticretinoids |
_version_ |
1721504501601402880 |